Esbriet and Ofev Use Aid IPF Patient Survival After Hospitalization

Esbriet and Ofev Use Aid IPF Patient Survival After Hospitalization

302962

Esbriet and Ofev Use Aid IPF Patient Survival After Hospitalization

Treatment with two approved antifibrotics did not lessen a risk of death in recently hospitalized idiopathic pulmonary fibrosis (IPF) patients, but those using either therapy who went on to be discharged were more likely to live longer than those who were not, a database study reported. “To our knowledge, this is the first use of real-world data to evaluate the impact of antifibrotics on hospitalization outcomes,” Andrew H. Limper, MD, a pulmonologist at the Mayo Clinic…

You must be logged in to read/download the full post.